Vanda Pharmaceuticals Inc.
VNDA
$6.42
$0.152.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 217.78M | 216.11M | 212.07M | 203.47M | 201.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 217.78M | 216.11M | 212.07M | 203.47M | 201.35M |
| Cost of Revenue | 12.68M | 13.04M | 11.80M | 11.40M | 11.40M |
| Gross Profit | 205.10M | 203.06M | 200.27M | 192.07M | 189.96M |
| SG&A Expenses | 256.23M | 237.95M | 214.26M | 191.56M | 166.41M |
| Depreciation & Amortization | 7.24M | 7.01M | 7.01M | 7.01M | 7.01M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 378.15M | 367.27M | 333.17M | 304.28M | 273.80M |
| Operating Income | -160.36M | -151.17M | -121.09M | -100.81M | -72.45M |
| Income Before Tax | -149.70M | -138.65M | -107.14M | -85.00M | -55.63M |
| Income Tax Expenses | 89.84M | 81.83M | -22.94M | -18.06M | -11.38M |
| Earnings from Continuing Operations | -239.55 | -220.47 | -84.20 | -66.94 | -44.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -239.55M | -220.47M | -84.20M | -66.94M | -44.25M |
| EBIT | -160.36M | -151.17M | -121.09M | -100.81M | -72.45M |
| EBITDA | -151.98M | -143.06M | -113.07M | -92.87M | -64.56M |
| EPS Basic | -4.05 | -3.74 | -1.43 | -1.14 | -0.76 |
| Normalized Basic EPS | -1.60 | -1.49 | -1.21 | -0.98 | -0.67 |
| EPS Diluted | -4.05 | -3.74 | -1.44 | -1.15 | -0.77 |
| Normalized Diluted EPS | -1.60 | -1.49 | -1.21 | -0.98 | -0.67 |
| Average Basic Shares Outstanding | 236.64M | 235.71M | 234.92M | 234.09M | 233.32M |
| Average Diluted Shares Outstanding | 236.64M | 235.71M | 234.92M | 234.09M | 233.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |